A Swiss Study With Atorvastatin in Hyperlipidemic Patients Measuring LDL-Cholesterol (ACTFAST SWISS)

Tracking Information
First Submitted Date ICMJE	August 25, 2005
First Posted Date ICMJE	August 29, 2005
Last Update Posted Date	March 3, 2008
Study Start Date ICMJE	April 2005
Primary Completion Date	Not Provided
Current Primary Outcome Measures ICMJE; (submitted: August 25, 2005)	The proportion of patients achieving LDL-C target as defined by local swiss AGLArecommendations across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.
Original Primary Outcome Measures ICMJE	Same as current
Change History	Complete list of historical versions of study NCT00136942 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ICMJE; (submitted: January 12, 2006)	The proportion of patients across different AGLA-categories (primary and secondary prevention) achieving LDL-C target as defined by AGLA-recommendations across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.
Original Secondary Outcome Measures ICMJE; (submitted: August 25, 2005)	The proportion of patients across different AGLA-categories (primary and secondary prevention) achieving LDL-C target as defined by AGLA-recommendations across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin. This will be measured the
Current Other Outcome Measures ICMJE	Not Provided
Original Other Outcome Measures ICMJE	Not Provided
Descriptive Information
Brief Title ICMJE	A Swiss Study With Atorvastatin in Hyperlipidemic Patients Measuring LDL-Cholesterol
Official Title ICMJE	A Multicenter, 6-Week-Treatment, Open-Label Study Assessing The Percentage Of Hyperlipidemic Patients Achieving Low Density Lipoprotein Cholesterol Target With Atorvastatin
Brief Summary	The proportion of patients achieving LDL-C target as defined by Swiss cholesterol recommendations (AGLA-recommendations) across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.
Detailed Description	Not Provided
Study Type ICMJE	Interventional
Study Phase	Phase 3
Study Design ICMJE	Allocation: Non-Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Treatment
Condition ICMJE	Hyperlipidemia
Intervention ICMJE	Drug: Atorvastatin
Study Arms	Not Provided
Publications *	Not Provided
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status ICMJE	Completed
Enrollment ICMJE; (submitted: August 25, 2005)	370
Original Enrollment ICMJE	Same as current
Study Completion Date	Not Provided
Primary Completion Date	Not Provided
Eligibility Criteria ICMJE	Inclusion Criteria: Risk factors and diagnosis of dyslipidemia according to the AGLA-recommendations (see appendix B) at screening; LDL-C < 6.0 mmol/l; Triglyceride level < 5.0 mmol/l. Exclusion Criteria: Subjects receiving higher than "usual maintenance" doses of Lipid Lowering Therapy (LLT) at screening.
Sex/Gender	Sexes Eligible for Study: All
Ages	18 Years to 80 Years (Adult, Older Adult)
Accepts Healthy Volunteers	No
Contacts ICMJE	Contact information is only displayed when the study is recruiting subjects
Listed Location Countries ICMJE	Switzerland
Removed Location Countries
Administrative Information
NCT Number ICMJE	NCT00136942
Other Study ID Numbers ICMJE	A2581089
Has Data Monitoring Committee	Not Provided
U.S. FDA-regulated Product	Not Provided
IPD Sharing Statement	Not Provided
Responsible Party	Not Provided
Study Sponsor ICMJE	Pfizer
Collaborators ICMJE	Not Provided
Investigators ICMJE	Study Director: Pfizer CT.gov Call Center Pfizer
PRS Account	Pfizer
Verification Date	April 2007
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP